Boris Sepesi, MD, of The University of Texas MD Anderson Cancer Center, discusses immune cells within tumors and the potential role for checkpoint inhibitor therapy in the neoadjuvant setting of locally advanced lung cancer (Abstract 7).
Zofia Piotrowska, MD, of the Massachusetts General Hospital Cancer Center, discusses heterogeneity and variation in resistance mechanisms among EGFR-mutant non–small cell lung cancer patients with at least one postresistance biopsy (Abstract 1).
Tracey L. Evans, MD, of the University of Pennsylvania, discusses the data supporting use of chemotherapy with radiation in locally advanced non–small cell lung cancer, targeted treatments and immunotherapy, and some of the controversies now debated.
Zhongxing Liao, MD, of The University of Texas MD Anderson Cancer Center, discusses the continued improvement in planning, delivery, and patient selection for proton therapy, which can both reduce radiation exposure and increase tumor dose.
Shraddha M. Dalwadi, MBA, MD Candidate in the class of 2017 at Texas A&M Health Science Center, discusses findings from a SEER database study that showed African Americans and American Indians with stage I non–small cell lung cancer were less likely to receive definitive treatment and had lower odds for survival (Abstract 9).
Martin J. Edelman, MD, of Fox Chase Cancer Center, discusses study findings from a phase III study of celecoxib in addition to standard chemotherapy for advanced non–small cell lung cancer with COX-2 overexpression (Abstract 2).
